Rivaroxaban

CAS 366789-02-8 59 API suppliersSmall Molecule

Overview

Rivaroxaban is an oral anticoagulant used to prevent and treat blood clots. It works as a direct factor Xa inhibitor, which disrupts the blood coagulation cascade.

API suppliers (60)

Suppliers of Rivaroxaban evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

Where these suppliers are
India32China12Israel1Netherlands1Malta1Canada1Peru1USA1

Country recorded for 52 of 60 suppliers.

30 of 60 hold a GMP certificate on record in the EU or UK registers · 1 holds a European CEP for this substance

Showing 25 of 60 suppliers — see the full list in the app.

Patent & exclusivity (US)

Per the FDA Orange Book (68 approved US products), the latest listed US patent on Rivaroxaban expires 17 Aug 2034. Generic API sourcing typically opens up once these lapse.

Therapeutic areas

CardiovascularHematology
Verified Supplier Partner

Do you supply Rivaroxaban? Get in front of buyers actively sourcing it.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.